Sildenafil
Also known as: sildenafil citrate, Viagra, Revatio
Classification
Pharmaceutical
Regulatory Status
FDA-approved prescription product
Sources
2
Review
n/a
Overview
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP and promoting smooth-muscle relaxation in the corpus cavernosum and pulmonary vasculature as described in product labeling.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved sildenafil products (e.g., Viagra) are labeled for erectile dysfunction. Educational reference only.
FDA-approved sildenafil products (e.g., Revatio) are labeled for pulmonary arterial hypertension as specified in product labeling. Educational reference only.
Interactions & cautions
Flagged in source data
Drug interactions
organic nitrates (e.g., nitroglycerin) — Profound hypotension; potentially fatal. (high)
riociguat — Hypotension risk. (high)
strong CYP3A4 inhibitors — Increased exposure and adverse effects. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw